FDA Grants Approval for Amneal's Phytonadione ANDA217734
The FDA has granted approval for Amneal's Abbreviated New Drug Application for Phytonadione.
Published: July 22, 2026
Updated: July 22, 2026
Author: Humanexa Intelligence
Therapeutic area: Hematology / Vitamin K
Asset: Amneal
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Asset
Amneal
Indication
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's approval of Amneal's Phytonadione presents a significant shift in the vitamin K market landscape, increasing competition. Portfolio teams must evaluate the implications for their existing products and strategize to safeguard market share.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor market entry timelines and pricing strategies from Amneal following this approval.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.